Recent updates on development of drug molecules for human African trypanosomiasis

Current Topics in Medicinal Chemistry

Volumn 16, Issue 20, 2016, Pages 2245-2265

  Grewal, Ajmer Singh ^a   Pandita, Deepti ^a   Bhardwaj, Shashikant ^a   Lather, Viney ^a  

^a JCDM College of Pharmacy   (India)

Author keywords

African trypanosomiasis; Anti trypanosoma agents; HAT; Sleeping sickness; Treatment of HAT; Trypanosoma brucei

Indexed keywords

(2S) AMINO[(5S) 3 BROMO 4,5 DIHYDRO 1,2 OXAZOL 5 YL]ACETIC ACID; 1 (3,4 DICHLOROPHENYL) 4 NITRO 1H IMIDAZOLE; 1 METHYL 2 ((4 (METHYLSULFANYL)PHENOXY)METHYL) 5 NITRO 1HIMIDAZOLE 4 SULFONIC ACID; 2 AMINO 5 (1 METHYL 5 NITRO 2 IMIDAZOLYL) 1,3,4 THIADIAZOLE; 2 CHLORO N (4 HEXYLPHENYL) 5 NITROBENZAMIDE; 2 [(5 NITROFURAN 2 YL)METHYL] 2,3,4,9 TETRAHYDRO 1H B CARBOLINE; 2,5 BIS(4 AMIDINOPHENYL)FURAN; 3 BROMO N’ METHOXY 4 {[3 (N’ METHOXYCARBAMIMIDOYL)PHENYL]METHOXY}BENZENE 1 CARBOXIMIDAMIDE; 4 FLUORO N (1 HYDROXY 3,3 DIMETHYL 1,3DIHYDRO BENZO[C][1,2]OXABOROL 6 YL 2 TRIFLUOROMETHYL BENZAMIDE; 7 NITRO 1,2,3,3A TETRAHYDROPYRROLO[1,2 A]QUINOXALIN 4(5H) ONE; ACIVICIN; ANTITRYPANOSOMAL AGENT; ASCIDIDEMIN; BERBERINE; CYNAROPICRIN; EFLORNITHINE; FEXINIDAZOLE; HAEMANTHAMINE; INDATRALINE; MELARSEN; MELARSOPROL; N 3(3 (4,5 DIHYDRO 1H IMIDAZOL 2YL)PHENYL) 4 (4 ((3 (4,5 DIHYDO 1H IMIDAZOL 2 YL)PHENYL)CARBAMOYL)PHENYL)BENZAMIDE; NIFURTIMOX; NITROFURAL; N’ METHOXY 6 {5 [4 (N’ METHOXYCARBAMIMIDOYL)PHENYL]FURAN 2 YL}PYRIDINE 3 CARBOXIMIDAMIDE; OCTYL 2 [(5 NITROFURAN 2 YL)METHYLIDENE]HYDRAZINE 1 CARBOXYLATE; PAFURAMIDINE; PENTAMIDINE; SURAMIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ARTICLE; CHEMICAL STRUCTURE; CHEMOTHERAPY; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PHENOTYPE; PREVALENCE; SLEEP DISORDER; TRYPANOSOMIASIS, AFRICAN;

HUMANS; TRYPANOCIDAL AGENTS; TRYPANOSOMIASIS, AFRICAN;

EID: 84975687807     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026616666160413125335     Document Type: Article

References (132)

1. Simarro, P.P.; Diarra, A.; Ruiz Postigo, J.A.; Franco, J.R.; Jannin, J.G. The human African trypanosomiasis control and surveillance programme of the World Health Organization 2000-2009: The way forward. PLoS Negl. Trop. Dis., 2011, 5, e1007.
2. Cox, F.E. History of sleeping sickness (African trypanosomiasis). Infect. Dis. Clin. North Am., 2004, 18(2), 231-245.
3. Steverding, D. The history of African trypanosomiasis. Parasit. Vectors, 2008, 1, 3.
4. Brun, R.; Blum, J.; Chappuis, F.; Burri, C. Human African trypanosomiasis. Lancet, 2010, 375, 148-159.
5. Cattand, P.; Jannin, J.G.; Lucas, P. Sleeping sickness surveillance: An essential step towards elimination. Trop. Med. Int. Health, 2001, 6, 348-361.
6. Simarro, P.P.; Cecchi, G.; Paone, M.; Franco, J.R.; Diarra, A.; Ruiz, J.A.; Fevre, E.M.; Courtin, F.; Mattioli, R.C.; Jannin, J.G. The atlas of human African trypanosomiasis: A contribution to global mapping of neglected tropical diseases. Int. J. Health Geogr., 2010, 9, 57.
7. Vanhamme, L. The human trypanolytic factor: A drug shaped naturally. Infect. Disord. Drug Targets, 2010, 10(4), 266-282.
8. Barrett, M.P. The rise and fall of sleeping sickness. Lancet, 2006, 367, 1377-1378.
9. Chappuis, F.; Lima, M.A.; Flevaud, L.; Ritmeijer, K. Human African trypanosomiasis in areas without surveillance. Emerg. Infect. Dis., 2010, 16, 354-356.
10. Sudarshi, D.; Brown, M. Human African trypanosomiasis in nonendemic countries. Clin. Med., 2015, 15, 70-73.
11. Urech, K.; Neumayr, A.; Blum, J. Sleeping sickness in travelers-do they really sleep? PLoS Negl. Trop. Dis., 2011, 5(11), e1358.
12. Lejon, V.; Buscher, P. Review Article: Cerebrospinal fluid in human African trypanosomiasis: A key to diagnosis, therapeutic decision and post-treatment follow-up. Trop. Med. Int. Health, 2005, 10, 395-403.
13. Malvy, D.; Djossou, F.; Longy-Boursier, M.; Le Bras, M.; Weill, F.X.; Chapuis, P.; Malvy D.; Djossou, F.; Weill, F.X.; Chapuis, P.; Longy-Boursier, M.; Le Bras, M. Guess What! Human West African trypanosomiasis with chancre presentation. Eur. J. Dermatol., 2000, 10, 561-562.
14. Gautret, P.; Clerinx, J.; Caumes, E.; Simon, F.; Jensenius, M.; Loutan, L.; Schlagenhauf, P.; Castelli, F.; Freedman, D.; Miller, A.; Bronner, U.; Parola, P. Imported human African trypanosomiasis in Europe, 2005-2009. Euro Surveill., 2009, 14, pii=19327.
15. Ezzedine, K.; Darie, H.; Le Bras, M.; Malvy, D. Skin features accompanying imported human African trypanosomiasis: Hemolymphatic Trypanosoma brucei gambiense infection among two French expatriates with dermatologic manifestations. J. Travel Med., 2007, 14, 192-196.
16. Bedat-Millet, A.L.; Charpentier, S.; Monge-Strauss, M.F.; Woimant, F. Psychiatric presentation of human African trypanosomiasis: Overview of diagnostic pitfalls, interest of difluoromethylornithine treatment and contribution of magnetic resonance imaging. Rev. Neurol. (Paris), 2000, 156, 505-509.
17. Duggan, A.L.; Hutchinson, M.P. Sleeping sickness in Europeans: A review of 109 cases. J. Trop. Med. Hyg., 1966, 69, 124-131.
18. Spencer, H.C.J.; Gibson, J.J. Jr; Brodsky, R.E.; Schultz, M.G. Imported African trypanosomiasis in the United States. Ann. Intern. Med., 1975, 82, 633-638.
19. Moore, D.A.; Edwards, M.; Escombe, R.; Agranoff, D.; Bailey, J.W.; Squire, S.B.; Chiodini, P.L. African trypanosomiasis in travellers returning to the United Kingdom. Emerg. Infect. Dis., 2002, 8, 74-76.
20. The National Travel Health Network and Centre. Trypanosomiasis in a traveller to Zimbabwe. Available at: http://www.nathnac.org/travel/news/Tryps_231012.html (Accessed 23 July 2015).
21. Vincendeau, P.; Bouteille, B. Immunology and immunopathology of African trypanosomiasis. An. Acad. Bras. Cienc., 2006, 78, 645-665.
22. Checci, F.; Filipe, J.A.; Haydon, D.T.; Chandramohan, D.; Chappuis, F. Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect. Dis., 2008, 8, 16.
23. Kennedy, P.G. Human African trypanosomiasis—neurological aspects. J. Neurol., 2006, 253, 411-416.
24. Blum, J.A.; Schmid, C.; Hatz, C.; Kazumba, L.; Mangoni, P.; Rutishauser, J.; la Torre, A.; Burri, C. Sleeping glands?-The role of endocrine disorders in sleeping sickness (T.b. gambiense Human African Trypanosomiasis). Acta Trop., 2007, 104(1), 16-24.
25. Malvy, D.; F. Chappuis, F. Sleeping sickness. Clin. Microbiol. Infect., 2011, 17, 986-995.
26. Lutumba, P.; Makieya, E.; Shaw, A.; Meheus, F.; Boelaert, M. Human African trypanosomiasis in a rural community, Democratic Republic of Congo. Emerg. Infect. Dis., 2007, 13(2), 248-254.
27. Mpanya, A.; Hendrickx, D.; Vuna, M.; Kanyinda, A.; Lumbala, C.; Tshilombo, V.; Mitashi, P.; Luboya, O.; Kande, V.; Boelaert, M.; Lefevre, P.; Lutumba, P. Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo. PLoS Negl. Trop. Dis., 2012, 6(1), e1467.
28. Garcia-Salcedo, J.A.; Munday, J.C.; Unciti-Broceta, J.D.; Koning, H.P. In: Trypanosomes and trypanosomiasis; Stefan Magez and Magdalena Radwanska, Ed.; Springer: Vienna, 2014; pp. 217-238.
29. Ferrins, L.; Rahmani, R.; Baell, J.B. Drug discovery and human African trypanosomiasis: A disease less neglected? Future Med. Chem., 2013, 5(15), 1801-1841.
30. WHO: Drugs. Human African Trypanosomiasis. http://www.who.int/trypanosomiasis_african/drugs/en (Accessed 28July 2015).
31. Voogd, T.E.; Vansterkenburg, E.L.; Wilting, J.; Janssen, L.H. Recent research on the biological activity of suramin. Pharmacol. Rev., 1993, 45(2), 177-203.
32. Seebeck, T.; Maser, P. In: Antimicrobial Drug Resistance. DL Mayers, Ed.; Humana Press: New York, 2009; pp. 589-604.
33. Meyskens, F.L. Jr.; Gerner, E.W. Development of difluoromethylornithine (DFMO) as a chemopreventive agent. Clin. Cancer Res., 1999, 5, 945-951.
34. Priotto, G.; Kasparian, S.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Karunakara, U. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: A randomized clinical trial in Congo. Clin. Infect. Dis., 2007, 45(11), 1435-1442.
35. Priotto, G.; Kasparian, S.; Mutombo, W.; Ngouama, D.; Ghorashian, S.; Arnold, U.; Ghabri, S.; Baudin, E.; Buard, V.; Kazadi-Kyanza, S.; Ilunga, M.; Mutangala, W.; Pohlig, G.; Schmid, C.; Karunakara, U.; Torreele, E.; Kande, V. Nifurtimoxeflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: A multicentre, randomised, phase III, non-inferiority trial. Lancet, 2009, 374(9683), 56-64.
36. Alirol, E.; Schrumpf, D.; Amici Heradi, J.; Riedel, A.; de Patoul, C.; Quere, M.; Chappuis, F. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clin. Infect. Dis., 2013, 56(2), 195-203.
37. Barrett, M.P. Potential new drugs for human African trypanosomiasis: Some progress at last. Curr. Opin. Infect. Dis., 2010, 23(6), 603-608.
38. Ismail, M.A.; Brun, R.; Tanious, F.A.; Wilson, W.D.; Boykin, D.W. Synthesis and anti-protozoal activity of aza-analogues of furamidine. J. Med. Chem., 2003, 46, 4761-4769.
39. Thuita, J.K.; Wang, M.Z.; Kagira, J.M.; Denton, C.L.; Paine, M.F.; Mdachi, R.E.; Murilla, G.A.; Ching, S.; Boykin, D.W.; Tidwell, R.R.; Hall, J.E.; Brun, R. Pharmacology of DB844, an orally active aza analogue of pafuramidine, in a monkey model of second stage human African trypanosomiasis. PLoS Negl. Trop. Dis., 2012, 6(7), e1734.
40. Patrick, D.A.; Bakunov, S.A.; Bakunova, S.M.; Jones, S.K.; Wenzler, T.; Barszcz, T.; Kumar, A.; Boykin, D.W.; Werbovetz, K.A.; Brun, R.; Tidwell, R.R. Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives. Eur. J. Med. Chem., 2013, 67, 310-324.
41. Yang, G.; Zhu, W.; Wang, Y.; Huang, G.; Byun, S.Y.; Choi, G.; Li, K.; Huang, Z.; Docampo, R.; Oldfield, E.; No, J.H. In Vitro and in Vivo Activity of Multitarget Inhibitors against Trypanosoma brucei. ACS Infect. Dis., 2015, 1(8), 388-398.
42. Steverding, D. The development of drugs for treatment of sleeping sickness: A historical review. Parasit. Vectors, 2010, 3(1), 15.
43. Tamborini, L.; Pinto, A.; Smith, T.K.; Major, L.L.; Iannuzzi, M.C.; Cosconati, S.; Marinelli, L.; Novellino, E.; Lo Presti, L.; Wong, P.E.; Barrett, M.P.; De Micheli, C.; Conti, P. Synthesis and biological evaluation of CTP synthetase inhibitors as potential agents for the treatment of African trypanosomiasis. Chem.Med. Chem., 2012, 7(9), 1623-1634.
44. Evens, F.; Niemegeers, K.; Packchanian, A. Nitrofurazone therapy of Trypanosoma gambiense sleeping sickness in man. Am. J. Trop. Med. Hyg., 1957, 6(4), 665-678.
45. Torreele, E.; Bourdin Trunz, B.; Tweats, D.; Kaiser, M.; Brun, R.; Mazue, G.; Bray, M.A.; Pecoul, B. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl. Trop. Dis., 2010, 4(12):e923.
46. Bot, C.; Hall, B.S.; Alvarez, G.; Di Maio, R.; Gonzalez, M.; Cerecetto, H.; Wilkinson, S.R. Evaluating 5-nitrofurans as trypanocidal agents. Antimicrob. Agents Chemother., 2013, 57(4), 1638-1647.
47. Samant, B.S.; Sukhthankar, M.G. Compounds containing 2-substituted imidazole ring for treatment against human African trypanosomiasis. Bioorg. Med. Chem. Lett., 2011, 21(3), 1015-1018.
48. Trunz, B.B.; Jędrysiak, R.; Tweats, D.; Brun, R.; Kaiser, M.; Suwiński, J.; Torreele, E. 1-Aryl-4-nitro-1H-imidazoles, a new promising series for the treatment of human African trypanosomiasis. Eur. J. Med. Chem., 2011, 46(5), 1524-1535.
49. Hwang, J.Y.; Smithson, D.; Connelly, M.; Maier, J.; Zhu, F.; Guy, K.R. Discovery of halonitrobenzamides with potential application against human African trypanosomiasis. Bioorg. Med. Chem. Lett., 2010, 20(1), 149-152.
50. Samant, B.S.; Chakaingesu, C. Novel naphthoquinone derivatives: Synthesis and activity against human African trypanosomiasis. Bioorg. Med. Chem. Lett., 2013, 23(5), 1420-1423.
51. Aran, V.J.; Kaiser, M.; Dardonville, C. Discovery of nitroheterocycles active against African trypanosomes. In vitro screening and preliminary SAR studies. Bioorg. Med. Chem. Lett., 2012, 22(14), 4506-4516.
52. de Carvalho, A.S.; Salomao, K.; de Castro, S.L.; Conde, T.R.; da Silva Zamith, H.P.; Caffarena, E.R.; Hall, B.S.; Wilkinson, S.R.; Boechat, N. Megazol and its bioisostere 4H-1,2,4-triazole: Comparing the trypanocidal, cytotoxic and genotoxic activities and their in vitro and in silico interactions with the Trypanosoma brucei nitroreductase enzyme. Mem. Inst. Oswaldo Cruz., Rio de Janeiro, 2014, 109(3), 315-323.
53. Manda, S.; Khan, S.I.; Jain, S.K.; Mohammed, S.; Tekwani, B.L.; Khan, I.A.; Vishwakarma, R.A.; Bharate, S.B. Synthesis, antileishmanial and antitrypanosomal activities of N-substituted tetrahydro-β-carbolines. Bioorg. Med. Chem. Lett., 2014, 24(15), 3247-3250.
54. Jacobs, R.T.; Nare, B.; Wring, S.A.; Orr, M.D.; Chen, D.; Sligar, J.M.; Jenks, M.X.; Noe, R.A.; Bowling, T.S.; Mercer, L.T.; Rewerts, C.; Gaukel, E.; Owens, J.; Parham, R.; Randolph, R.; Beaudet, B.; Bacchi, C.J.; Yarlett, N.; Plattner, J.J.; Freund, Y.; Ding, C.; Akama, T.; Zhang, Y.K.; Brun, R.; Kaiser, M.; Scandale, I.; Don, R. SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human African trypanosomiasis. PLoS Negl. Trop. Dis., 2011, 5(6), e1151.
55. Nare, B.; Wring, S.; Bacchi, C.; Beaudet, B.; Bowling, T.; Brun, R.; Chen, D.; Ding, C.; Freund, Y.; Gaukel, E.; Hussain, A.; Jarnagin, K.; Jenks, M.; Kaiser, M.; Mercer, L.; Mejia, E.; Noe, A.; Orr, M.; Parham, R.; Plattner, J.; Randolph, R.; Rattendi, D.; Rewerts, C.; Sligar, J.; Yarlett, N.; Don, R.; Jacobs, R. Discovery of novel orally bioavailable oxaborole 6-carboxamides that demonstrate cure in a murine model of late-stage central nervous system African trypanosomiasis. Antimicrob. Agents. Chemother., 2010, 54(10), 4379-4388.
56. Ding, D.; Meng, Q.; Gao, G.; Zhao, Y.; Wang, Q.; Nare, B.; Jacobs, R.; Rock, F.; Alley, M.R.; Plattner, J.J.; Chen, G.; Li, D.; Zhou, H. Design, synthesis, and structure-activity relationship of Trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents. J. Med. Chem., 2011, 54(5), 1276-1287.
57. Wu, P.; Zhang, J.; Meng, Q.; Nare, B.; Jacobs, R.T.; Zhou, H. Novel pyrrolobenzoxaboroles: Design, synthesis, and biological evaluation against Trypanosoma brucei. Eur. J. Med. Chem., 2014, 81, 59-75.
58. Frearson, J.A.; Brand, S.; McElroy, S.P.; Cleghorn, L.A.; Smid, O.; Stojanovski, L.; Price, H.P.; Guther, M.L.; Torrie, L.S.; Robinson, D.A.; Hallyburton, I.; Mpamhanga, C.P.; Brannigan, J.A.; Wilkinson, A.J.; Hodgkinson, M.; Hui, R.; Qiu, W.; Raimi, O.G.; van Aalten, D.M.; Brenk, R.; Gilbert, I.H.; Read, K.D.; Fairlamb, A.H.; Ferguson, M.A.; Smith, D.F.; Wyatt, P.G. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature, 2010, 464(7289), 728-732.
59. Diaz, R.; Luengo-Arratta, S.A.; Seixas, J.D.; Amata, E.; Devine, W.; Cordon-Obras, C.; Rojas-Barros, D.I.; Jimenez, E.; Ortega, F.; Crouch, S.; Colmenarejo, G.; Fiandor, J.M.; Martin, J.J.; Berlanga, M.; Gonzalez, S.; Manzano, P.; Navarro, M.; Pollastri, M.P. Identification and Characterization of Hundreds of Potent and Selective Inhibitors of Trypanosoma brucei Growth from a Kinase-Targeted Library Screening Campaign. PLoS Negl. Trop. Dis., 2014, 8(10), e3253.
60. Rashad, A.A.; Jones, A.J.; Avery, V.M.; Baell, J.; Keller, P.A. Facile synthesis and preliminary structure-activity analysis of new sulfonamides against Trypanosoma brucei. ACS Med. Chem. Lett., 2014, 5(5), 496-500.
61. Patterson, S.; Jones, D.C.; Shanks, E.J.; Frearson, J.A.; Gilbert, I.H.; Wyatt, P.G.; Fairlamb, A.H. Synthesis and evaluation of 1-(1-(Benzo[b]thiophen-2-yl)cyclohexyl)piperidine (BTCP) analogues as inhibitors of trypanothione reductase. ChemMedChem, 2009, 4(8), 1341-1353.
62. Richardson, J.L.; Nett, I.R.; Jones, D.C.; Abdille, M.H.; Gilbert, I.H.; Fairlamb, A.H. Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. ChemMedChem, 2009, 4(8), 1333-1340.
63. Berger, P.; Janowsky, A.; Vocci, F.; Skolnick, P.; Schweri, M.M.; Paul, S.M. [3H]GBR-12935: A specific high affinity ligand for labeling the dopamine transport complex. Eur. J. Pharmacol., 1985, 107(2), 289-290.
64. Holloway, G.A.; Baell, J.B.; Fairlamb, A.H.; Novello, P.M.; Parisot, J.P.; Richardson, J.; Watson, K.G.; Street, I.P. Discovery of 2-iminobenzimidazoles as a new class of trypanothione reductase inhibitor by high-throughput screening. Bioorg. Med. Chem. Lett., 2007, 17(5), 1422-1427.
65. Spinks, D.; Torrie, L.S.; Thompson, S.; Harrison, J.R.; Frearson, J.A.; Read, K.D.; Fairlamb, A.H.; Wyatt, P.G.; Gilbert, I.H. Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. ChemMedChem, 2012, 7(1), 95-106.
66. Patterson, S.; Alphey, M.S.; Jones, D.C.; Shanks, E.J.; Street, I.P.; Frearson, J.A.; Wyatt, P.G.; Gilbert, I.H.; Fairlamb, A.H. Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: Discovery, synthesis, and characterization of their binding mode by protein crystallography. J. Med. Chem., 2011, 54(19), 6514-6530.
67. Patel, G.; Karver, C.E.; Behera, R.; Guyett, P.J.; Sullenberger, C.; Edwards, P.; Roncal, N.E.; Mensa-Wilmot, K.; Pollastri, M.P. Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. J. Med. Chem., 2013, 56(10), 3820-3832.
68. Smithson, D.C.; Lee, J.; Shelat, A.A.; Phillips, M.A.; Guy, R.K. Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. J. Biol. Chem., 2010, 285(22), 16771-16781.
69. Bosc, D.; Lethu, S.; Mouray, E.; Grellier, P.; Dubois, J. Improvement of the trypanocidal activity of 3-arylthiophene farnesyltransferase inhibitors by modulation of their 3-aryl group. MedChem-Comm, 2012, 3(12), 1512-1517.
70. Waag, T.; Gelhaus, C.; Rath, J.; Stich, A.; Leippe, M.; Schirmeister, T. Allicin and derivatives are cysteine protease inhibitors with antiparasitic activity. Bioorg. Med. Chem. Lett., 2010, 20(18), 5541-5543.
71. Langolf, S.; Machon, U.; Ehlers, M.; Sicking, W.; Schirmeister, T.; Buchhold, C.; Gelhaus, C.; Rosenthal, P.J.; Schmuck, C. Development of antitrypanosomal and antiplasmodial nonpeptidic cysteine protease inhibitors based on N-protected-guanidinofuran and-pyrrole building blocks. ChemMedChem, 2011, 6(9), 1581-1586.
72. Yang, P.-Y.; Wang, M.; Li, L.; Wu, H.; He, C.Y.; Yao, S.Q. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents. Chemistry, 2012, 18(21), 6528-6541.
73. Vicik, R.; Hoerr, V.; Glaser, M.; Schultheis, M.; Hansell, E.; McKerrow, J.H.; Holzgrabe, U.; Caffrey, C.R.; Ponte-Sucre, A.; Moll, H.; Stich, A.; Schirmeister, T. Aziridine-2,3-dicarboxylate inhibitors targeting the major cysteine protease of Trypanosoma brucei as lead trypanocidal agents. Bioorg. Med. Chem. Lett., 2006, 16(10), 2753-2757.
74. Breuning, A.; Degel, B.; Schulz, F.; Buchold, C.; Stempka, M.; Machon, U.; Heppner, S.; Gelhaus, C.; Leippe, M.; Leyh, M.; Kisker, C.; Rath, J.; Stich, A.; Gut, J.; Rosenthal, P.J.; Schmuck, C.; Schirmeister, T. Michael acceptor based antiplasmodial and antitrypanosomal cysteine protease inhibitors with unusual amino acids. J. Med. Chem., 2010, 53(5), 1951-1963.
75. Sykes, M.L.; Baell, J.B.; Kaiser, M.; Chatelain, E.; Moawad, S.R.; Ganame, D.; Ioset, J.R.; Avery, V.M. Identification of compounds with antiproliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign. PLoS Negl. Trop. Dis., 2012, 6(11), e1896.
76. Ferrins, L.; Rahmani, R.; Sykes, M.L.; Jones, A.J.; Avery, V.M.; Teston, E.; Almohaywi, B.; Yin, J.; Smith, J.; Hyland, C.; White, K.L.; Ryan, E.; Campbell, M.; Charman, S.A.; Kaiser, M.; Baell, J.B. 3-(oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis. Eur. J. Med. Chem., 2013, 66, 450-465.
77. Jones, D.C.; Hallyburton, I.; Stojanovski, L.; Read, K.D.; Frearson, J.A.; Fairlamb, A.H. Identification of a k-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis. Biochem. Pharmacol., 2010, 80(10), 1478-1486.
78. Mercer, L.; Bowling, T.; Perales, J.; Freeman, J.; Nguyen, T.; Bacchi, C.; Yarlett, N.; Don, R.; Jacobs, R.; Nare, B. 2,4-diaminopyrimidines as potent inhibitors of Trypanosoma brucei and identification of molecular targets by a chemical proteomics approach. PLoS Negl. Trop. Dis., 2011, 5(2), e956.
79. Manos-Turvey, A.; Watson, E.E.; Sykes, M.L.; Jones, A.J.; Baell, J.B.; Kaiser, M.; Avery, V.M.; Payne, R.J. Synthesis and evaluation of phenoxymethylbenzamide analogues as anti-trypanosomal agents. Med. Chem. Commun., 2015, 6, 403-406.
80. Pedro-Rosa, L.; Buckner, F.S.; Ranade, R.M.; Eberhart, C.; Madoux, F.; Gillespie, J.R.; Koh, C.Y.; Brown, S.; Lohse, J.; Verlinde, C.L.; Fan, E.; Bannister, T.; Scampavia, L.; Hol, W.G.; Spicer, T.; Hodder, P. Identification of potent inhibitors of the Trypanosoma brucei methionyl-tRNA synthetase via high-throughput orthogonal screening. J. Biomol. Screen., 2015, 20(1), 122-130.
81. Tatipaka, H.B.; Gillespie, J.R.; Chatterjee, A.K.; Norcross, N.R.; Hulverson, M.A.; Ranade, R.M.; Nagendar, P.; Creason, S.A.; McQueen, J.; Duster, N.A.; Nagle, A.; Supek, F.; Molteni, V.; Wenzler, T.; Brun, R.; Glynne, R.; Buckner, F.S.; Gelb, M.H. Substituted 2-phenylimidazopyridines: A new class of drug leads for human African trypanosomiasis. J. Med. Chem., 2014, 57(3), 828-835.
82. Urich, R.; Grimaldi, R.; Luksch, T.; Frearson, J.A.; Brenk, R.; Wyatt, P.G. The design and synthesis of potent and selective inhibitors of Trypanosoma brucei glycogen synthase kinase 3 for the treatment of human African trypanosomiasis. J. Med. Chem., 2014, 57(18), 7536-7549.
83. Ochiana, S.O.; Bland, N.D.; Settimo, L.; Campbell, R.K.; Pollastri, M.P. Repurposing human PDE4 inhibitors for neglected tropical diseases. Evaluation of analogs of the human PDE4 inhibitor GSK-256066 as inhibitors of PDEB1 of Trypanosoma brucei. Chem. Biol. Drug Des., 2015, 85(5), 549-564.
84. Rahmani, R.; Ban, K.; Jones, A.J.; Ferrins, L.; Ganame, D.; Sykes, M.L.; Avery, V.M.; White, K.L.; Ryan, E.; Kaiser, M.; Charman, S.A.; Baell, J.B. 6-Arylpyrazine-2-carboxamides: A new core for Trypanosoma brucei inhibitors. J. Med. Chem., 2015, Aug 6 [Epub ahead of print].
85. Mott, B.T.; Ferreira, R.S.; Simeonov, A.; Jadhav, A.; Ang, K.K.; Leister, W.; Shen, M.; Silveira, J.T.; Doyle, P.S.; Arkin, M.R.; McKerrow, J.H.; Inglese, J.; Austin, C.P.; Thomas, C.J.; Shoichet, B.K.; Maloney, D.J. Identification and optimization of inhibitors of trypanosomal cysteine proteases: Cruzain, rhodesain, and TbCatB. J. Med. Chem., 2009, 53(1), 52-60.
86. Mallari, J.P.; Shelat, A.; Kosinski, A.; Caffrey, C.R.; Connelly, M.; Zhu, F.; McKerrow, J.H.; Guy, R.K. Discovery of trypanocidal thiosemicarbazone inhibitors of rhodesain and TbCatB. Bioorg. Med. Chem. Lett., 2009, 18(9), 2883-2885.
87. Hiltensperger, G.; Jones, N.G.; Niedermeier, S.; Stich, A.; Kaiser, M.; Jung, J.; Puhl, S.; Damme, A.; Braunschweig, H.; Meinel, L.; Engstler, M.; Holzgrabe, U. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei. J. Med. Chem., 2012, 55(6), 2538-2548.
88. Wube, A.; Hufner, A.; Seebacher, W.; Kaiser, M.; Brun, R.; Bauer, R.; Bucar, F. 1, 2-Substituted 4-(1H)-Quinolones: Synthesis, antimalarial and antitrypanosomal activities in vitro. Molecules, 2014, 19, 14204-14220.
89. Pomel, S.; Dubar, F.; Forge, D.; Loiseau, P.M.; Biot, C. New heterocyclic compounds: Synthesis and antitrypanosomal properties. Bioorg. Med. Chem., 2015, 23(16), 5168-5174.
90. Woodland, A.; Grimaldi, R.; Luksch, T.; Cleghorn, L.A.; Ojo, K.K.; Van Voorhis, W.C.; Brenk, R.; Frearson, J.A.; Gilbert, I.H.; Wyatt, P.G. From on-target to off-target activity: Identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. ChemMedChem, 2013, 8(7), 1127-1137.
91. Deterding, A.; Dungey, F.A.; Thompson, K.-A.; Steverding, D. Anti-trypanosomal activities of DNA topoisomerase inhibitors. Acta Tropica., 2005, 93(3), 311-316.
92. Bolognesi, M.L.; Lizzi, F.; Perozzo, R.; Brun, R.; Cavalli, A. Synthesis of a small library of 2-phenoxy-1,4-naphthoquinone and 2-phenoxy-1,4-anthraquinone derivatives bearing anti-trypanosomal and antileishmanial activity. Bioorg. Med. Chem. Lett., 2008, 18(7), 2272-2276.
93. Belluti, F.; Uliassi, E.; Veronesi, G.; Bergamini, C.; Kaiser, M.; Brun, R.; Viola, A.; Fato, R.; Michels, P.A.; Krauth-Siegel, R.L.; Cavalli, A.; Bolognesi, M.L. Toward the development of dualtargeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi. ChemMedChem, 2014, 9(2), 371-382.
94. Jansen, C.; Wang, H.; Kooistra, A.J.; de Graaf, C.; Orrling, K.M.; Tenor, H.; Seebeck, T.; Bailey, D.; de Esch, I.J.; Ke, H.; Leurs, R. Discovery of novel Trypanosoma brucei phosphodiesterase B1 inhibitors by virtual screening against the unliganded TbrPDEB1 crystal structure. J. Med. Chem., 2013, 56(5), 2087-2096.
95. Orrling, K.M.; Jansen, C.; Lan Vu, X.; Balmer, V.; Bregy, P.; Shanmugham, A.; England, P.; Bailey, D.; Cos, P.; Maes, L.; Adams, E.; van den Bogaart, E.; Chatelain, E.; Ioset, J.R.; van de Stolpe, A.; Zorg, S.; Veerman, J.; Seebeck, T.; Sterk, G.J.; de Esch, I.J.P.; Leurs, R. Catechol pyrazolinones as trypanocidals: Fragmentbased design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1. J. Med. Chem., 2012, 55(20), 8745-8756.
96. Ruda, G.F.; Wong, P.E.; Alibu, V.P.; Norval, S.; Read, K.D.; Barrett, M.P.; Gilbert, I.H. Aryl phosphoramidates of 5-phosphoerythronohydroxamic acid, a new class of potent trypanocidal compounds. J. Med. Chem., 2010, 53(16), 6071-6078.
97. Papanastasiou, I.; Tsotinis, A.; Kolocouris, N.; Prathalingam, S.R.; Kelly, J.M. Design, synthesis, and trypanocidal activity of new aminoadamantane derivatives. J. Med. Chem., 2008, 51(5), 1496-1500.
98. Weis, R.; Seebacher, W. New bicyclic amines: Synthesis and SARs of their action against the causative organisms of malaria and sleeping sickness. Curr. Med. Chem., 2009, 16(11), 1426-1441.
99. Spencer, J.; Rathnam, R.P.; Harvey, A.L.; Clements, C.J.; Clark, R.L.; Barrett, M.P.; Wong, P.E.; Male, L.; Coles, S.J.; Mackay, S.P. Synthesis and biological evaluation of 1,4-benzodiazepin-2-ones with antitrypanosomal activity. Bioorg. Med. Chem., 2011, 19(5), 1802-1815.
100. Maiwald, F.; Benitez, D.; Charquero, D.; Dar, M.A.; Erdmann, H.; Preu, L.; Koch, O.; Holscher, C.; Loaec, N.; Meijer, L.; Comini, M.A.; Kunick, C. 9-and 11-Substituted 4-azapaullones are potent and selective inhibitors of African trypanosoma. Eur. J. Med. Chem., 2014, 83, 274-283.
101. Velasquez, A.M.; Francisco, A.I.; Kohatsu, A.A.; Silva, F.A.; Rodrigues, D.F.; Teixeira, R.G.; Chiari, B.G.; de Almeida, M.G.; Isaac, V.L.; Vargas, M.D.; Cicarelli, R.M. Synthesis and tripanocidal activity of ferrocenyl and benzyl diamines against Trypanosoma brucei and Trypanosoma cruzi. Bioorg. Med. Chem. Lett., 2014, 24(7), 1707-1710.
102. Havrylyuk, D.; Zimenkovsky, B.; Karpenko, O.; Grellier, P.; Lesyk, R. Synthesis of pyrazoline-thiazolidinone hybrids with trypanocidal activity. Eur. J. Med. Chem., 2014, 85, 245-254.
103. Woodring, J.L.; Patel, G.; Erath, J.; Behera, R.; Lee, P.J.; Leed, S.E.; Rodriguez, A.; Sciotti, R.J.; Mensa-Wilmot, K.; Pollastri, M.P. Evaluation of aromatic 6-substituted thienopyrimidines as scaffolds against parasites that cause trypanosomiasis, leishmaniasis, and malaria. MedChemComm., 2015, 6, 339-346.
104. Hoet, S.; Opperdoes, F.; Brun, R.; Quetin-Leclercq, J. Natural products active against African trypanosomes: A step towards new drugs. Nat. Prod. Rep., 2004, 21(3), 353-364.
105. Gehrig, S.; Efferth, T. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review). Int. J. Mol. Med., 2008, 22(4), 411-419.
106. Salem, M.M.; Werbovetz, K.A. Natural products from plants as drug candidates and lead compounds against leishmaniasis and trypanosomiasis. Curr. Med. Chem., 2006, 13(21), 2571-2598.
107. Ioset, J.R. Natural products for neglected diseases: A review. Curr. Org. Chem., 2008, 12(8), 643-666.
108. Noor, R.A.; Khozirah, S.; Mohd Ridzuan M.A.R.; Ong, B.K.; Rohaya, C.; Rosilawati, M.; Hamdina, I.; Badrul, A.; Zakiah, I. Antiplasmodial properties of some Malaysian medicinal plants. Trop. Biomed., 2007, 24, 29-35.
109. Norhayati, I.; Getha, K.; Haffiz, J.H.; Ilham, A.M.; Sahira, H.L.; Siti, Syarifah M.M.; Syamil, A.M. In vitro antitrypanosomal activity of Malaysian plants. J. Trop. For. Sci., 2013, 25, 52-59.
110. Otoguro, K.; Ishiyama, A.; Namatame, M.; Nishihara, A.; Furusawa, T.; Masuma, R.; Shiomi, K.; Takahashi, Y.; Yamada, H.; Omura, S. Selective and potent in vitro antitrypanosomal activites of ten microbial metabolites. J. Antibiot., 2008, 61, 372-378.
111. Otoguro, K.; Iwatsuki, M.; Ishiyama, A.; Namatame, M.; Tukashima, A.N.; Kiyohara, H.; Hashimoto, T.; Asakawa, Y.; Omura, S.; Yamada, H. In vitro antitrypanosomal activity of plant terpenes against Trypanosoma brucei. Phytochem., 2011, 72, 2024-2030.
112. Hofer, A.; Steverding, D.; Chabes, A.; Brun, R.; Thelander, L. Trypanosoma brucei CTP synthetase: A target for the treatment of African sleeping sickness. Proc. Natl. Acad. Sci. U S A, 2001, 98(11), 6412-6416.
113. Navarro, G.; Chokpaiboon, S.; De Muylder, G.; Bray, W.M.; Nisam, S.C.; McKerrow, J.H.; Pudhom, K.; Linington, R.G. Hit-tolead development of the chamigrane endoperoxide merulin A for the treatment of African sleeping sickness. PLoS One, 2012, 7(9), e46172.
114. Gros, L.; Castillo-Acosta, V.M.; Jimenez Jimenez, C.; Sealey-Cardona, M.; Vargas, S.; Manuel Estevez, A.; Yardley, V.; Rattray, L.; Croft, S.L.; Ruiz-Perez, L.M.; Urbina, J.A.; Gilbert, I.H.; Gonzalez-Pacanowska, D. New azasterols against Trypanosoma brucei: Role of 24-sterol methyltransferase in inhibitor action. Antimicrob. Agents Chemother., 2006, 50(8), 7.
115. Schmidt, T.J.; Nour, A.M.; Khalid, S.A.; Kaiser, M.; Brun, R. Quantitative structure-antiprotozoal activity relationships of sesquiterpene lactones. Molecules, 2009, 14(6), 2062-2076.
116. Orhan, I.; Sener, B.; Kaiser, M.; Brun, R.; Tasdemir, D. Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar. Drugs, 2010, 8(1), 47-58.
117. Watts, K.R.; Ratnam, J.; Ang, K.H.; Tenney, K.; Compton, J.E.; McKerrow, J.; Crews, P. Assessing the trypanocidal potential of natural and semi-synthetic diketopiperazines from two deep water marine-derived fungi. Bioorg. Med. Chem., 2010, 18, 2566-2574.
118. Carballeira, N.M.; Cartagena, M.; Sanabria, D.; Tasdemir, D.; Prada, C.F.; Reguera, R.M.; Balana-Fouce, R. 2-alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. Bioorg. Med. Chem. Lett., 2012, 22(19), 6185-6189.
119. Bonazzi, S.; Barbaras, D.; Patiny, L.; Scopelliti, R.; Schneider, P.; Cole, S.T.; Kaiser, M.; Brun, R.; Gademann, K. Antimalarial and antitubercular nostocarboline and eudistomin derivatives: Synthesis, in vitro and in vivo biological evaluation. Bioorg. Med. Chem., 2010, 18(4), 1464-1476.
120. Lavrado, J.; Mackey, Z.; Hansell, E.; Mckerrow, J.H.; Paulo, A.; Moreira, R. Antitrypanosomal and cysteine protease inhibitory activities of alkyldiamine cryptolepine derivatives. Bioorg. Med. Chem. Lett., 2012, 22(19), 6256-6260.
121. Feng, Y.; Davis, R.A.; Sykes, M.L.; Avery, V.M.; Carroll, A.R.; Camp, D.; Quinn, R.J. Antitrypanosomal pyridoacridine alkaloids from the Australian ascidian Polysyncraton echinatum. Tetrahedron Lett., 2010, 51(18), 2477-2479.
122. Merschjohann, K.; Sporer, F.; Steverding, D.; Wink, M. In vitro effect of alkaloids on bloodstream forms of Trypanosoma brucei and T. congolense. Planta Med., 2001, 67(7), 623-627.
123. Endeshaw, M.; Zhu, X.; He, S.; Pandharkar, T.; Cason, E.; Mahasenan, K.V.; Agarwal, H.; Li, C.; Munde, M.; Wilson, W.D.; Bahar, M.; Doskotch, R.W.; Kinghorn, A.D.; Kaiser, M.; Brun, R.; Drew, M.E.; Werbovetz, K.A. 8,8-dialkyldihydroberberines with potent antiprotozoal activity. J. Nat. Prod., 2013, 76(3), 311-315.
124. Scala, F.; Fattorusso, E.; Menna, M.; Taglialatela-Scafati, O.; Tierney, M.; Kaiser, M.; Tasdemir, D. Bromopyrrole alkaloids as lead compounds against protozoan parasites. Mar. Drugs, 2010, 8(7), 2162-2174.
125. Calcul, L.; Inman, W.D.; Morris, A.A.; Tenney, K.; Ratnam, J.; McKerrow, J.H.; Valeriote, F.A.; Crews, P. Additional insights on the bastadins: Isolation of analogues from the sponge Ianthella cf. reticulata and exploration of the oxime configurations. J. Nat. Prod., 2010, 73(3), 365-372.
126. Wang, X.; Beckham, T.H.; Morris, J.C.; Chen, F.; Gangemi, J.D. Bioactivities of gossypol, 6-methoxygossypol, and 6,6´-dimethoxygossypol. J. Agric. Food Chem., 2008, 56(12), 4393-4398.
127. Ebrahimi, S.N.; Zimmermann, S.; Zaugg, J.; Smiesko, M.; Brun, R.; Hamburger, M. Abietane diterpenoids from Salvia sahendicaantiprotozoal activity and determination of their absolute configurations. Planta Med., 2013, 79(2), 150-156.
128. Minagawa, N.; Yabu, Y.; Kita, K.; Nagai, K.; Ohta, N.; Meguro, K.; Sakajo, S.; Yoshimoto, A. An antibiotic, ascofuranone, specifically inhibits respiration and in vitro growth of long slender bloodstream forms of Trypanosoma brucei brucei. Mol. Biochem. Parasitol., 1997, 84(2), 271-280.
129. Yabu, Y.; Suzuki, T.; Nihei, C.; Minagawa, N.; Hosokawa, T.; Nagai, K.; Kita, K.; Ohta, N. Chemotherapeutic efficacy of ascofuranone in Trypanosoma vivax-infected mice without glycerol. Parasitol. Int., 2006, 55(1), 39-43.
130. Schulze, C.J.; Donia, M.S.; Siqueira-Neto, J.L.; Ray, D.; Raskatov, J.A.; Green, R.E.; McKerrow, J.H.; Fischbach, M.A.; Linington, R.G. Genome-Directed Lead Discovery: Biosynthesis, Structure Elucidation, and Biological Evaluation of Two Families of Polyene Macrolactams against Trypanosoma brucei. ACS Chem. Biol., 2015, DOI: 10.1021/acschembio.5b00308.
131. Brun, R.; Balmer, O. New developments in human African trypanosomiasis. Curr. Opin. Infect Dis., 2006, 19(5), 415-420.
132. Brun, R.; Don, R.; Jacobs, R.T.; Wang, M.Z.; Barrett, M.P. Development of novel drugs for human African trypanosomiasis. Future Microbiol., 2011, 6(6), 677-691.